• Treatment and prevention of osteoporosis in postmenopausal women:
    • PO 150mg every month OR IV 3mg every 3 months administered over 15-30 seconds

Tablet: 150mg

  • Give with water 60min before first food/drink/drug
  • Avoid lying down for 60min
  • Calcium and vitamin D supplementation recommended if inadequate dietary intake
  • Avoid invasive dental procedure

Bisphosphonate

It inhibits osteoclast activity, reducing bone resorption and turnover.

  • Arthralgia
  • Influenza
  • Back pain
  • Hypertension
  • Abdominal pain
  • Influenza-like symptoms
  • Hypercholesterolemia
  • Dyspepsia
  • Nausea
  • Constipation
  • Headache
  • URI
  • UTI
  • Dizziness
  • Fatigue
  • Rash
  • Diarrhea
  • Extremity pain
  • Gastritis
  • Myalgia
  • Insomnia
  • Depression
  • Localized osteoarthritis
  • Muscle cramps
  • Hypersensitivity; anaphylaxis reported, including fatalities
  • Uncorrected hypocalcemia
  • Inability to stand or sit upright for at least 60 min
  • Esophagus abnormalities that delay emptying (e.g, stricture, achalasia)
  • CrCl <30
  • Invasive dental procedure (IV use)
  • Recombinant human parathyroid hormone

                          Drug Status

Availability Prescription only
Pregnancy Not indicated
Breastfeeding Not indicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Baron 150mg Tablet 1’s Dawa Ltd Dawa Ltd
Bondronat 6mg/6mL Injection 1’s F. Hoffman-La Roche Surgipharm Ltd
Bonviva 3mg/3mL Pre-Filled Syringe 1’s F. Hoffman-La Roche Surgipharm Ltd
Bonviva 150mg Tablet 1’s F. Hoffman-La Roche Surgipharm Ltd
Cadronate 150mg Tablet 3’s Galaxy Pharma Galaxy Pharma